HOOKIPA Phase 2 HB-200 data: 43% ORR with pembrolizumab vs 19% historical; pivotal trial planned for 2024

HOOKIPA Pharma Inc.

HB-200 + pembrolizumab showed 43% objective response rate (6/14 patients) in 1st-line HPV16+ head/neck cancer, doubling pembrolizumab alone.
Median overall survival of 14.2 months in heavily pre-treated monotherapy cohort (n=11, median follow-up 12.8 months).
Safety: 7% serious adverse events related to HB-200; 2% discontinuation rate across 132 patients.
Company preparing to start pivotal trial of HB-200 + pembrolizumab in 1st-line setting in 2024.
HB-200 induced rapid, sustained T-cell responses for at least 8 months associated with clinical benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.